Document is current
Any future updates will be listed below
-
Authors
Lin, Kung-Hung
Vilar-Gomez, Eduardo
Corey, Kathleen E.
Connelly, Margery A.
Gupta, Samir K.
Lake, Jordan E.
Chalasani, Naga
Gawrieh, Samer
-
Funding
Funding for this research was provided by:
National Institutes of Health (DK112293, DK112293, DK112293, DK112293)
- License Information
-
More Information
Article History
Received: 27 November 2023
Accepted: 26 September 2024
First Online: 17 October 2024
Declarations
:
: This study protocol had been reviewed and approved by each site’s the Institutional Review Board (Indiana University School of Medicine, Massachusetts General Hospital, and, UTHealth Science Center). Each participant provided written informed consent.
: Dr. Lin and Dr. Vilar-Gomez declare no conflicts of interest. Dr. Corey serves on the scientific advisory board for Theratechnologies, Novo Nordisk and BMS and has received grant funding from Boehringer-Ingelheim, BMS and Novartis, Dr. Connelly is an employee of and holds stock in Labcorp, Dr. Gupta receives consultancy fees from ViiV Healthcare and Gilead Sciences and unrestricted research grant funding from ViiV Healthcare, Dr. Lake serves as a consultant to CytoDyn and Theratechnologies, and receives research support from Gilead Sciences and Zydus Pharmaceuticals, Dr. Chalasani declares none for this paper. For full disclosure, he has had paid consulting agreements with Madrigal, GSK, Galectin, Zydus, Altimune, Foresite, Ventyx, Merck and Pfizer. He has research grants from DSM and Exact Sciences. He has equity ownership in Avant Sante Therapeutics, a contract research organization., Dr. Gawrieh consulting: TransMedics, Pfizer. Research grant support: Viking and Zydus.
